GOG GYN-LIVE - INDUSTRY SUPPORTED SYMPOSIA

This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease. Faculty will provide expert insights on current treatment paradigms, including immunotherapy, chemotherapy, and novel combinations. Through integrated patient case discussions, the session will highlight how molecular profiling drives...

This course offers a clinically relevant exploration of evolving treatment strategies in ovarian and endometrial cancers for a global audience.  The primary focus of this course will help learners understand how to make biomarker-driven decisions for on-label therapeutic pathways. Learners will deepen their understanding of the role of BRCA, HRD, MMR/MSI, and emerging biomarkers such as p53 for eq...

This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease. Faculty will provide expert insights on current treatment paradigms, including immunotherapy, chemotherapy, and novel combinations. Through integrated patient case discussions, the session will highlight how molecular profiling drives...

Minimal Residual Disease (MRD) testing using circulating tumor DNA (ctDNA) has emerged as a promising tool for improving the management of gynecologic malignancies, including endometrial, ovarian, and cervical cancers. This 90-minute course explores the evolving role of ctDNA in identifying disease recurrence and assessing treatment response—potentially earlier than imaging or traditional biomarke...

This educational program offers a comprehensive and clinically relevant exploration of the rapidly evolving endometrial cancer treatment landscape, with a particular focus understanding the dynamic and evolving competitive landscape. The curriculum is designed to address the need for deeper clarity around differences in trial design, key efficacy outcomes, and therapeutic positioning.   Through a...

This educational session explores the evolving global landscape of advanced and recurrent cervical cancer, with a focus on disparities in access to care and treatment innovations. Participants will review pivotal clinical trial data shaping current treatment paradigms, including the role of antibody-drug conjugates (ADCs) as a novel therapeutic option. Emphasis will be placed on how to compare and...

While antibody-drug conjugates (ADCs) have reshaped therapeutic paradigms, the latest clinical trial results reveal a broader array of opportunities, spanning novel mechanisms of action, immunotherapy-based combinations, and molecularly targeted strategies. Through rigorous analysis of newly presented efficacy and safety data, including key PFS/OS endpoints, expert faculty will provide context and...

This symposium will explore the rapidly evolving landscape of treatment for recurrent low-grade serous ovarian cancer (LGSOC), with a focus on newly FDA-approved therapies and investigational strategies, MEC Inhibitors, CDK46 Inhibitors, hormonal treatments and other opportunities in the competitive landscape. LGSOC remains a challenging subtype due to its unique biology and resistance to conventi...